Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street

Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street

Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news. With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).